share_log

Veru (VERU) to Release Earnings on Thursday

Veru (VERU) to Release Earnings on Thursday

Veru(VERU)将于周四发布财报
Defense World ·  2023/02/02 02:21

Veru (NASDAQ:VERU – Get Rating) will release its earnings data before the market opens on Thursday, February 9th. Analysts expect Veru to post earnings of ($0.38) per share for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.

Veru(纳斯达克股票代码:VERU — Get Rating)将在2月9日星期四开市前发布其收益数据。分析师预计,Veru将公布本季度每股收益(0.38美元)。有兴趣报名参加公司财报电话会议的人可以使用此链接进行注册。

Veru (NASDAQ:VERU – Get Rating) last posted its quarterly earnings data on Monday, December 5th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.22). The firm had revenue of $2.59 million for the quarter, compared to analysts' expectations of $11.51 million. Veru had a negative net margin of 212.88% and a negative return on equity of 69.57%. On average, analysts expect Veru to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Veru(纳斯达克股票代码:VERU — Get Rating)最后一次发布季度收益数据是在12月5日星期一。该公司报告本季度每股收益(EPS)(0.51美元),比分析师普遍预期的(0.29美元)低于(0.22美元)。该公司本季度的收入为259万美元,而分析师的预期为1151万美元。Veru的净利润率为负212.88%,负股本回报率为69.57%。分析师平均预计,Veru将在本财年公布每股收益为-1美元,下一财年每股收益为-1美元。

Get
获取
Veru
Veru
alerts:
警报:

Veru Stock Up 2.4 %

Veru 股票上涨了 2.4%

VERU opened at $5.90 on Thursday. The firm has a market capitalization of $475.66 million, a P/E ratio of -5.62 and a beta of -0.27. The firm's 50 day moving average is $5.57 and its 200-day moving average is $10.26. Veru has a 52-week low of $4.34 and a 52-week high of $24.55.

VERU周四开盘价为5.90美元。该公司的市值为4.7566亿美元,市盈率为-5.62,beta值为-0.27。该公司的50天移动平均线为5.57美元,其200天移动平均线为10.26美元。Veru创下52周低点4.34美元,52周高点为24.55美元。

Institutional Trading of Veru

Veru 的机构交易

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Principal Financial Group Inc. bought a new stake in Veru during the second quarter valued at $114,000. LPL Financial LLC bought a new stake in Veru during the second quarter valued at $124,000. Envestnet Asset Management Inc. bought a new stake in Veru during the third quarter valued at $130,000. XTX Topco Ltd increased its stake in Veru by 18.7% during the first quarter. XTX Topco Ltd now owns 14,426 shares of the company's stock valued at $70,000 after purchasing an additional 2,270 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV increased its stake in Veru by 36.7% during the third quarter. Mercer Global Advisors Inc. ADV now owns 15,634 shares of the company's stock valued at $180,000 after purchasing an additional 4,196 shares during the last quarter. Institutional investors own 48.87% of the company's stock.
一些对冲基金和其他机构投资者最近对该股的头寸进行了调整。信安金融集团公司在第二季度收购了Veru的新股份,价值11.4万美元。LPL Financial LLC在第二季度收购了Veru的新股份,价值12.4万美元。Envestnet Asset Management Inc.在第三季度收购了Veru的新股份,价值13万美元。XTX Topco Ltd在第一季度将其在Veru的股份增加了18.7%。XTX Topco Ltd在上个季度又购买了2270股股票后,现在拥有该公司14,426股股票,价值7万美元。最后,美世环球顾问公司ADV在第三季度将其在Veru的股份增加了36.7%。Mercer Global Advisors Inc.ADV在上个季度又购买了4,196股股票后,现在拥有该公司15,634股股票,价值18万美元。机构投资者拥有该公司48.87%的股份。

Analyst Ratings Changes

分析师评级变化

Separately, HC Wainwright dropped their price objective on shares of Veru from $21.00 to $18.00 and set a "buy" rating on the stock in a research note on Wednesday, December 7th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $33.50.

另外,HC Wainwright在12月7日星期三的一份研究报告中将Veru股票的目标价格从21.00美元下调至18.00美元,并对该股设定了 “买入” 评级。五位股票研究分析师对该股进行了买入评级,根据MarketBeat的数据,该股目前的平均评级为 “买入”,共识目标价为33.50美元。

About Veru

关于 Veru

(Get Rating)

(获取评分)

Veru, Inc is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer, VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer, and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT.

Veru, Inc是一家肿瘤生物制药公司,致力于开发用于治疗前列腺癌和乳腺癌的新药物。其前列腺癌候选药物包括:VERU-111,一种口服 α和β微管蛋白抑制剂,正在进行治疗转移性去势和雄激素受体靶向药物耐药性前列腺癌的 2 期临床试验;VERU-100,一种旨在解决晚期前列腺癌市售雄激素剥夺疗法 (ADT) 当前局限性的新型、专有的 GnRH 拮抗剂肽药物配方;以及口服非甾酸珠氯米芬正在开发用于治疗潮热的类雌激素受体激动剂,ADT 引起的常见副作用。

Featured Stories

精选故事

  • Get a free copy of the StockNews.com research report on Veru (VERU)
  • Bed Bath & Beyond Is Circling the Drain
  • Allegro Microsystems Is A Well-Positioned Semiconductor Stock
  • Scotts Miracle-Gro Hits Bottom, Reversal In Play
  • Altria is a Great Recession Stock, Long-Term Outlook Uncertain
  • Novavax Shares Jumped in January While Others Slipped
  • 免费获取 StockNews.com 关于 Veru (VERU) 的研究报告的副本
  • Bed Bath & Beyond 正在排水管中盘旋
  • Allegro Microsystems 是一家定位良好的半导体
  • Scotts Miracle-Gro 触底,在比赛中逆转
  • 奥驰亚是大萧条股票,长期前景不确定
  • Novavax股价在1月份上涨,而其他股则下滑

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.

接收 Veru Daily 的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Veru及相关公司的最新新闻和分析师评级的简要每日摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发